CVS Health Reports Mixed Q4 & Full-Year 2025 Results, Lowers 2026 Cash Flow Guidance Amid Significant Charges

summarizeSummary

CVS Health announced mixed Q4 and full-year 2025 results, featuring record revenues but a significant goodwill impairment and legacy litigation charges. The company also lowered its 2026 cash flow guidance, signaling potential future liquidity concerns.

check_boxKey Events

• Full-Year 2025 Adjusted EPS Increased, GAAP EPS Declined

  CVS Health reported full-year 2025 total revenues of $402.1 billion, up 7.8%, and Adjusted EPS of $6.75, up from $5.42 in the prior year. However, GAAP diluted EPS for the full year decreased significantly to $1.39 from $3.66, primarily due to non-recurring charges.

• Significant Goodwill Impairment and Legacy Litigation Charges

  The company recorded a $5.7 billion goodwill impairment charge related to its Health Care Delivery reporting unit and approximately $1.2 billion in legacy litigation charges during the full year 2025, materially impacting GAAP operating income and net income.

• 2026 Cash Flow Guidance Lowered

  CVS Health updated its 2026 full-year cash flow from operations guidance to at least $9.0 billion, a reduction from its previous guidance of at least $10.0 billion.

• Q4 2025 Adjusted EPS Decreased

  For the fourth quarter of 2025, Adjusted EPS decreased to $1.09 from $1.19 in the prior year, primarily due to a decline in adjusted operating income in the Health Care Benefits segment, reflecting changes in Medicare Part D program seasonality.

auto_awesomeAnalysis

CVS Health reported record full-year revenues and strong adjusted EPS growth for 2025. However, the report is significantly impacted by a substantial $5.7 billion goodwill impairment charge related to its Health Care Delivery unit and $1.2 billion in legacy litigation charges, which severely reduced GAAP diluted EPS for the full year. Furthermore, the company lowered its 2026 cash flow from operations guidance from at least $10.0 billion to at least $9.0 billion, indicating a weaker outlook for future liquidity. The Health Care Benefits segment also experienced an adjusted operating loss in Q4 2025 and a year-over-year decline in medical membership. These negative factors, particularly the large non-recurring charges and the reduced cash flow guidance, overshadow the positive revenue trends and adjusted earnings growth, suggesting underlying operational and legal challenges.